Finasteride is an oral treatment for male pattern baldness caused by sensitivity to dihydrotestosterone (DHT). It is prescribed for adult men with progressive hair loss and works by reducing the hormone signal that gradually shrinks scalp hair follicles.
Finasteride belongs to the 5-alpha-reductase inhibitor class. Its active substance, finasteride, reduces the conversion of testosterone into dihydrotestosterone, or DHT. DHT is an androgen hormone involved in male pattern baldness, also called androgenetic alopecia.
The medicine is taken for hair loss in adult men. Finasteride for male pattern baldness is intended for adult men.
Key points include:
In genetically sensitive follicles, DHT shortens the active growth phase of the hair cycle. Each new hair may become finer, shorter, and less pigmented. Over time, the follicle can produce only a thin, barely visible hair.
This process is called follicle miniaturisation. It usually affects the temples, hairline, and crown, while the sides and back of the scalp remain less sensitive to DHT. Finasteride targets the hormonal pathway driving this process rather than acting as a cosmetic thickener.
Finasteride acts throughout the body after oral administration. That systemic action explains both its usefulness and its potential to affect sexual function or mood.
Finasteride reduced scalp DHT in the clinical evidence reviewed for the FDA-approved hair-loss indication [1].
Finasteride is not suitable for everyone. The medicine is not for you if:
Finasteride does not replace evaluation of urinary symptoms, blood in the urine, pelvic pain, or suspected prostate cancer. The FDA prescribing information describes the effects of finasteride on PSA interpretation and prostate-related monitoring [5].
Pregnant women must not handle crushed or broken Finasteride pills. The active substance can interfere with development of male external genitalia in a developing fetus.
Tell the prescriber about liver disease, prostate symptoms, fertility concerns, mood disorders, and all medicines or supplements. Finasteride can lower prostate-specific antigen, or PSA, and this affects how PSA results are interpreted during prostate assessment. Always state that you take Finasteride before a PSA test.
Finasteride is often tolerated without serious problems, yet sexual and psychological effects deserve a direct explanation. Reported reactions include reduced sexual desire, difficulty getting or maintaining an erection, reduced ejaculate volume, and ejaculation problems. Some men notice these effects soon after starting treatment; others report them later.
The NHS lists sexual side effects among recognised adverse effects and advises attention to persistent or troublesome symptoms [2]. The frequency in clinical studies varies by study design, patient population, and whether symptoms were actively assessed.
Possible reactions include:
Mood changes need prompt attention. Persistent sadness, loss of interest, severe anxiety, thoughts of self-harm, or suicidal thoughts require urgent clinical assessment. The MHRA has issued safety advice about psychiatric adverse effects and sexual dysfunction associated with finasteride [3].
Some men feel embarrassed discussing erection or ejaculation changes. That delay can make treatment decisions harder. A prescriber can assess whether symptoms began after Finasteride, whether another condition contributes, and whether a change in treatment is appropriate.
Persistent symptoms after discontinuation have been reported, although the frequency and causal relationship remain difficult to establish for every individual. This possibility should be discussed if symptoms continue after treatment changes.
Seek urgent help for facial or throat swelling, breathing difficulty, severe depression, or suicidal thoughts. Those symptoms require immediate attention rather than waiting for a routine review.
The active substance is finasteride, a 5-alpha-reductase inhibitor that reduces the conversion of testosterone into dihydrotestosterone (DHT).
Finasteride is taken by mouth as a pill at the prescribed dose and frequency. For hair loss, treatment is usually scheduled regularly, because intermittent use does not maintain the intended suppression of DHT.
Practical administration points include:
Visible improvement is gradual. Reduced shedding may become noticeable after several months, while a fuller assessment of hair density generally requires longer continuous treatment. The NHS describes the need for ongoing use because hair loss can return after stopping [4].
The crown may respond more visibly than a receding hairline. Early fine hairs can be easy to miss in ordinary bathroom lighting, so judging progress every few days often creates unnecessary worry. A consistent photographic record taken under similar lighting is more useful than daily inspection.
Shedding can fluctuate during treatment. A temporary change in hair fall does not prove that the treatment has failed, while continued rapid loss after an adequate treatment period deserves clinical review for other causes such as thyroid disease, iron deficiency, alopecia areata, or scalp inflammation.
Hair-loss treatments differ in their target, route, and effect on DHT. Finasteride lowers DHT through an oral systemic mechanism. Minoxidil acts mainly on the hair follicle environment and does not reduce DHT. Dutasteride inhibits more forms of 5-alpha-reductase and may produce a stronger DHT reduction, though its use for hair loss depends on local prescribing practice.
| Treatment approach | Main mechanism and route | Main limitation |
|---|---|---|
| Finasteride | Oral 5-alpha-reductase inhibition; lowers DHT | Can cause sexual or mood-related adverse effects |
| Minoxidil | Topical or oral follicle-growth support, depending on formulation | Benefit depends on continued use; topical irritation may occur |
| Dutasteride | Broader 5-alpha-reductase inhibition; systemic treatment | Greater hormonal suppression and prescribing restrictions in some settings |
Finasteride may suit an adult man seeking an oral treatment directed at the hormonal driver of male pattern baldness. Minoxidil may be selected when avoiding systemic DHT reduction is a priority, though topical application can be inconvenient and may cause scalp irritation.
Dutasteride acts on both type 1 and type 2 5-alpha-reductase, while Finasteride has a narrower enzyme target. A broader mechanism does not automatically make it the better first choice. The longer persistence of dutasteride in the body and its broader hormonal activity can affect treatment selection.
Clinical studies of oral finasteride and topical minoxidil support different benefit profiles, so the choice depends on diagnosis, tolerance, sex, age, and treatment goals. Finasteride is not appropriate for women who are pregnant or may become pregnant because of the risk posed to a male fetus.
Several habits make Finasteride harder to assess:
One common error is judging treatment by the shower drain. Hair shedding naturally varies, and the amount visible on one day does not measure follicle activity accurately.
Another is assuming that a missed pill requires an extra tablet. It does not. The safer approach is to resume the normal schedule.
In clinical practice, doctors usually set expectations before treatment begins: Finasteride aims to slow progression first, and regrowth is less predictable. The best response often occurs when treatment starts while follicles are still producing miniaturised hairs. Treatment goals should be agreed before progress is judged. Photographs taken under consistent conditions can help compare change. A prescriber can review progress before deciding whether to continue.
A prescriber will usually confirm the pattern of hair loss rather than assuming every thinning pattern is male pattern baldness. Sudden shedding, patchy bald areas, scalp pain, scaling, or loss of eyebrows points toward other diagnoses that need a different assessment.
Doctors also ask about depression, suicidal thoughts, sexual function, fertility concerns, liver disease, and all current medicines. A patient does not need to use technical language. Saying “my erection changed two weeks after starting” is clinically useful.
The treatment is judged over months, not days. A response can be modest and still clinically meaningful if it preserves hair that would otherwise have been lost.
Pregnancy or the possibility of pregnancy rules out Finasteride use for women because finasteride can affect development of male fetal genitalia. The MHRA safety information available in 2024 continued to emphasise this handling risk for broken tablets. Adult men with male pattern baldness may be considered for treatment, while sudden patchy hair loss needs a different diagnostic assessment.
A single dose does not create a full course of hair-loss protection, because the treatment depends on repeated suppression of DHT over time. Finasteride has a relatively short plasma half-life, while its effect on the enzyme pathway continues beyond the time the medicine is measurable in blood. The FDA prescribing information from 2022 describes this pharmacological effect in its finasteride data. Missing one dose usually means taking the next scheduled dose without doubling it.
Finasteride lowers DHT by inhibiting 5-alpha-reductase, while Minoxidil supports hair growth through a different follicle-directed mechanism. Patient information from NICE, NHS, and the American Academy of Dermatology available through 2024 describes these approaches as distinct rather than interchangeable treatments. Finasteride is an oral systemic treatment; Minoxidil is commonly used topically, although oral formulations exist under separate prescribing decisions. The choice depends on diagnosis, tolerance, pregnancy considerations, and the person’s preference for systemic or topical treatment.
There is no universal interaction rule covering every antidepressant or supplement, so the specific product list matters. The MHRA’s 2024 safety communication focused on psychiatric symptoms and sexual dysfunction, which can also be affected by antidepressants. Herbal sexual-health products may contain pharmacologically active substances or undeclared ingredients and should not be added casually. Provide the prescriber with the exact names of all medicines and supplements before combining them.
Erectile dysfunction is a recognised possible adverse effect of Finasteride, along with reduced libido and ejaculation changes. NHS information reviewed in 2024 lists sexual problems among the effects requiring attention. The symptom can also result from anxiety, diabetes, vascular disease, depression, or another medicine, so timing and medical history are relevant. Persistent symptoms, severe distress, or loss of sexual function should prompt a medication review rather than self-treatment with supplements.
Finasteride is not used during pregnancy, and pregnant women should not handle crushed or broken pills. The FDA product information from 2022 identifies a risk to the development of male fetal genitalia from exposure to finasteride. Breastfeeding use is not appropriate because finasteride is intended for adult men and its hormonal effects are not suitable for this situation. Anyone who is pregnant, trying to conceive, or breastfeeding should not start or handle this treatment without specific medical direction.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
He described taking Finasteride. He felt that shedding had slowed and noticed more coverage at the crown, although the hairline changed very little. He had no sexual symptoms and found the main challenge was remembering the tablet on weekends.
He reported that his hair looked stable after regular use. During the first weeks, he noticed reduced libido and chose to discuss it with his prescriber rather than stopping without advice. The symptom later improved, but he remained cautious about continuing treatment.
He said that the treatment had not produced dramatic regrowth, yet photographs showed less progression at the crown. He found daily comparison unhelpful because bathroom lighting made the hair appear different from one day to the next.
He noticed fewer loose hairs and felt more comfortable styling his hair. He had expected a faster change and initially considered doubling the dose after a missed tablet, but followed the regular schedule instead.
